Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Bioscns (NQ: APTO )

0.6720 -0.0310 (-4.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,523
Open 0.7200
Bid (Size) 0.6833 (1)
Ask (Size) 0.7170 (1)
Prev. Close 0.7030
Today's Range 0.6710 - 0.7200
52wk Range 0.6700 - 5.100
Shares Outstanding 93,653,662
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-71.76%
-71.76%
1 Month
-22.76%
-22.76%
3 Month
-47.09%
-47.09%
6 Month
-69.87%
-69.87%
1 Year
-84.35%
-84.35%

More News

Read More
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
Recap: Aptose Biosciences Q4 Earnings
Via Benzinga
Aptose Biosciences's Earnings: A Preview
Via Benzinga
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024
Via InvestorPlace
Aptose Reports Results for the First Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences: Q3 Earnings Insights
Via Benzinga
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Aptose Reports Results for the Fourth Quarter and Full Year 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Via Benzinga
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
From Aptose Biosciences, Inc.
Via GlobeNewswire
Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts
Via InvestorPlace
Topics Economy Workforce
Exposures Economy Layoff
Why Is SU Group (SUGP) Stock Moving Today?
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
Why Is Aptose Biosciences (APTO) Stock Down Today?
Via InvestorPlace
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Third Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.